Thrombo-Inflammation: A Focus on NTPDase1/CD39.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
27 08 2021
Historique:
received: 29 07 2021
revised: 24 08 2021
accepted: 24 08 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 8 10 2021
Statut: epublish

Résumé

There is increasing evidence for a link between inflammation and thrombosis. Following tissue injury, vascular endothelium becomes activated, losing its antithrombotic properties whereas inflammatory mediators build up a prothrombotic environment. Platelets are the first elements to be activated following endothelial damage; they participate in physiological haemostasis, but also in inflammatory and thrombotic events occurring in an injured tissue. While physiological haemostasis develops rapidly to prevent excessive blood loss in the endothelium activated by inflammation, hypoxia or by altered blood flow, thrombosis develops slowly. Activated platelets release the content of their granules, including ATP and ADP released from their dense granules. Ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase1)/CD39 dephosphorylates ATP to ADP and to AMP, which in turn, is hydrolysed to adenosine by ecto-5'-nucleotidase (CD73). NTPDase1/CD39 has emerged has an important molecule in the vasculature and on platelet surfaces; it limits thrombotic events and contributes to maintain the antithrombotic properties of endothelium. The aim of the present review is to provide an overview of platelets as cellular elements interfacing haemostasis and inflammation, with a particular focus on the emerging role of NTPDase1/CD39 in controlling both processes.

Identifiants

pubmed: 34571872
pii: cells10092223
doi: 10.3390/cells10092223
pmc: PMC8469976
pii:
doi:

Substances chimiques

Antigens, CD 0
Nucleotides 0
Apyrase EC 3.6.1.5
CD39 antigen EC 3.6.1.5

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Med. 1999 Sep;5(9):1010-7
pubmed: 10470077
Purinergic Signal. 2006 Jun;2(2):409-30
pubmed: 18404480
Blood. 2013 Apr 18;121(16):3067-75
pubmed: 23380744
PLoS One. 2012;7(7):e40829
pubmed: 22792409
Clin Res Cardiol. 2020 Feb;109(2):137-160
pubmed: 31144065
J Extracell Vesicles. 2021 Apr;10(6):12084
pubmed: 33936566
Circ Res. 1989 Sep;65(3):531-7
pubmed: 2548757
Crit Care. 2020 Jun 16;24(1):353
pubmed: 32546188
J Thromb Haemost. 2006 Jun;4(6):1323-30
pubmed: 16706978
Nature. 2014 May 15;509(7500):310-7
pubmed: 24828189
Arterioscler Thromb Vasc Biol. 2002 Dec 1;22(12):2003-9
pubmed: 12482826
Front Pharmacol. 2019 Jul 11;10:775
pubmed: 31354490
PLoS Pathog. 2011 Jul;7(7):e1002110
pubmed: 21750674
Br J Pharmacol. 2010 Feb 1;159(3):576-85
pubmed: 20067476
Purinergic Signal. 2014 Dec;10(4):611-8
pubmed: 25165006
Molecules. 2019 May 30;24(11):
pubmed: 31151201
Nat Commun. 2019 Apr 23;10(1):1916
pubmed: 31015489
Cardiovasc Res. 2011 Nov 1;92(2):328-37
pubmed: 21859817
Purinergic Signal. 2012 Sep;8(3):437-502
pubmed: 22555564
Nat Rev Immunol. 2013 Jan;13(1):34-45
pubmed: 23222502
Br J Haematol. 2008 Aug;142(4):627-37
pubmed: 18537971
Blood Rev. 2021 Jan;45:100694
pubmed: 32340775
Purinergic Signal. 2018 Mar;14(1):73-82
pubmed: 29236227
Life Sci. 1998;62(20):1817-24
pubmed: 9600323
EBioMedicine. 2020 Oct;60:102978
pubmed: 32920367
Cardiovasc Res. 2010 Jan 1;85(1):204-13
pubmed: 19640930
Circ Res. 2017 Jan 6;120(1):207-228
pubmed: 28057794
Cardiovasc Res. 2015 Aug 1;107(3):386-95
pubmed: 25712962
N Engl J Med. 2003 Jan 9;348(2):138-50
pubmed: 12519925
J Mol Cell Cardiol. 2011 Dec;51(6):927-35
pubmed: 21939667
Int J Inflam. 2014;2014:247503
pubmed: 24940514
Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1607-16
pubmed: 21512161
Biol Chem. 2015 Nov;396(11):1181-97
pubmed: 26040008
Front Immunol. 2018 Jun 11;9:1322
pubmed: 29942314
Am J Physiol Heart Circ Physiol. 2016 Jul 1;311(1):H286-98
pubmed: 27208163
Circulation. 2008 Aug 12;118(7):754-63
pubmed: 18663083
Nat Rev Cardiol. 2021 Sep;18(9):666-682
pubmed: 33958774
Semin Thromb Hemost. 2005 Apr;31(2):234-46
pubmed: 15852226
Purinergic Signal. 2017 Jun;13(2):259-265
pubmed: 28343356
QJM. 2003 Nov;96(11):793-807
pubmed: 14566035
J Immunol. 2019 Nov 1;203(9):2357-2367
pubmed: 31636134
Immunopharmacology. 1989 Jan-Feb;17(1):51-9
pubmed: 2651354
Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):870-8
pubmed: 22423039
Circ Res. 2015 Mar 27;116(7):1206-15
pubmed: 25645301
Crit Care Med. 2019 May;47(5):e420-e427
pubmed: 30730441
Diabetes. 2009 Apr;58(4):999-1006
pubmed: 19095759
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16788-93
pubmed: 19805374
Mol Cell Biochem. 2021 Aug;476(8):2891-2898
pubmed: 33740184
J Clin Invest. 2019 Apr 16;129(7):2872-2877
pubmed: 30990798
FASEB J. 2015 Jan;29(1):25-36
pubmed: 25318479
Circulation. 2004 Oct 26;110(17):2713-20
pubmed: 15492312
Trans Am Clin Climatol Assoc. 2018;129:132-139
pubmed: 30166707
Life Sci. 1997;60(2):PL31-8
pubmed: 9000123
Int J Mol Sci. 2019 Nov 03;20(21):
pubmed: 31684173
J Clin Med. 2021 Mar 04;10(5):
pubmed: 33806709
Biochem Biophys Res Commun. 2020 Jun 18;527(1):104-109
pubmed: 32446352
Curr Atheroscler Rep. 2014 Jul;16(7):425
pubmed: 24838375
Am J Pathol. 2012 Jul;181(1):322-33
pubmed: 22613024
Nature. 1998 Feb 5;391(6667):591-4
pubmed: 9468137
J Invest Dermatol. 2019 Mar;139(3):638-647
pubmed: 30367871
J Mol Med (Berl). 2013 Feb;91(2):165-72
pubmed: 23292173
Circ Res. 2015 Mar 13;116(6):1022-33
pubmed: 25767287
Blood Cells Mol Dis. 2006 Mar-Apr;36(2):217-22
pubmed: 16476557
J Autoimmun. 2018 Mar;88:131-138
pubmed: 29103803
J Exp Med. 1997 Jan 6;185(1):153-63
pubmed: 8996251
J Physiol. 2007 Mar 1;579(Pt 2):553-64
pubmed: 17204504
Ann N Y Acad Sci. 2010 Oct;1207:11-7
pubmed: 20955420
Nature. 1992 Oct 29;359(6398):848-51
pubmed: 1279433
Nat Immunol. 2013 Oct;14(10):1054-63
pubmed: 23995234
Nat Rev Dis Primers. 2015 May 07;1:15006
pubmed: 27189130
Heart Vessels. 2016 May;31(5):783-94
pubmed: 26062773
J Lipid Res. 2017 Jul;58(7):1292-1305
pubmed: 28487312
J Thromb Haemost. 2011 Jul;9 Suppl 1:182-8
pubmed: 21781254
FASEB J. 2017 Jul;31(7):2771-2784
pubmed: 28302652
Circ Res. 2009 Jul 17;105(2):109-11
pubmed: 19608987
J Am Heart Assoc. 2017 Jul 27;6(8):
pubmed: 28751543
J Clin Invest. 2015 Aug 3;125(8):3027-36
pubmed: 26121751
Purinergic Signal. 2015 Dec;11(4):411-34
pubmed: 26260710
Annu Rev Pathol. 2006;1:297-329
pubmed: 18039117
Arterioscler Thromb Vasc Biol. 2002 Mar 1;22(3):364-73
pubmed: 11884276
Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):e118-e129
pubmed: 30816804
Circulation. 2007 Oct 16;116(16):1784-94
pubmed: 17909107
J Physiol. 1984 Sep;354:419-29
pubmed: 6481640
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):403-12
pubmed: 18174460
Platelets. 2004 May;15(3):131-44
pubmed: 15203715
Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2562-70
pubmed: 26515417
Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8767-71
pubmed: 7522321
Purinergic Signal. 2011 Sep;7(3):357-65
pubmed: 21484090
Blood. 2015 Jul 9;126(2):242-6
pubmed: 25979951
Front Pharmacol. 2018 Jan 30;9:37
pubmed: 29441021
Handb Exp Pharmacol. 2020 Aug 11;:
pubmed: 32776281
Front Pharmacol. 2020 Jan 31;10:1689
pubmed: 32082171
Trends Cardiovasc Med. 2009 Jan;19(1):1-5
pubmed: 19467446
J Clin Invest. 2002 Apr;109(8):1031-40
pubmed: 11956240
Clin Immunol. 2020 Aug;217:108498
pubmed: 32531345
Eur Heart J. 2018 Jan 7;39(2):111-116
pubmed: 28472483
Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2216-21
pubmed: 16123325
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):401-414
pubmed: 33196292
Biochem Pharmacol. 2021 May;187:114373
pubmed: 33340515
Thromb Res. 1996 Sep 15;83(6):405-19
pubmed: 8885136
Trends Mol Med. 2013 Jun;19(6):355-67
pubmed: 23601906

Auteurs

Silvana Morello (S)

Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.

Elisabetta Caiazzo (E)

Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy.

Roberta Turiello (R)

Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.
PhD Program in Drug Discovery and Development, University of Salerno, 84084 Fisciano, Italy.

Carla Cicala (C)

Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH